Iain A Mcneish

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6887303/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	13.7	1,261
3	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
4	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	10.7	975
5	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
6	"Re-educating―tumor-associated macrophages by targeting NF-κB. Journal of Experimental Medicine, 2008, 205, 1261-1268.	8.5	700
7	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	1.2	665
8	Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, 2012, 366, 610-618.	27.0	651
9	A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor. Clinical Cancer Research, 2006, 12, 6737-6747.	7.0	514
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
11	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research, 2011, 17, 6083-6096.	7.0	330
12	Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. International Journal of Cancer, 2010, 126, 2762-2772.	5.1	321
13	Copy number signatures and mutational processes in ovarian carcinoma. Nature Genetics, 2018, 50, 1262-1270.	21.4	320
14	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	9.4	310
15	Mannose impairs tumour growth and enhances chemotherapy. Nature, 2018, 563, 719-723.	27.8	282
16	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	9.4	278
17	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology, 2017, 147, 267-275.	1.4	222
18	Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research, 2010, 16, 4005-4015.	7.0	217

#	Article	IF	CITATIONS
19	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology, 2011, 29, 3798-3804.	1.6	203
20	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	12.8	192
21	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology, The, 2018, 19, 1680-1687.	10.7	187
22	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer, 2019, 29, 728-760.	2.5	167
23	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
24	CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. Cancer Research, 2016, 76, 6118-6129.	0.9	145
25	Survivin: A Protein with Dual Roles in Mitosis and Apoptosis. International Review of Cytology, 2005, 247, 35-88.	6.2	143
26	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	13.7	142
27	Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment. Journal of Clinical Oncology, 2006, 24, 4862-4866.	1.6	137
28	Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. International Journal of Cancer, 2007, 120, 2344-2352.	5.1	126
29	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 2022, 40, 3952-3964.	1.6	125
30	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. Clinical Cancer Research, 2016, 22, 3025-3036.	7.0	124
31	Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell, 2021, 39, 1361-1374.e9.	16.8	122
32	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	12.8	116
33	Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Reports, 2020, 30, 481-496.e6.	6.4	111
34	Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells. Molecular and Cellular Biology, 2003, 23, 7600-7610.	2.3	105
35	Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors. Viruses, 2010, 2, 2290-2355.	3.3	104
36	Twenty-five years' clinical experience with placental site trophoblastic tumors. Journal of reproductive medicine, The, 2002, 47, 460-4.	0.2	104

#	Article	IF	CITATIONS
37	Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis. Cancer Immunology Research, 2020, 8, 1099-1111.	3.4	90
38	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	1.2	85
39	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 2017, 8, 14206.	12.8	81
40	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
41	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 2019, 154, 441-448.	1.4	74
42	Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression ofE. coli nitroreductase. International Journal of Cancer, 2000, 86, 848-854.	5.1	71
43	CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 2017, 7, 16827.	3.3	68
44	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 2022, 33, 276-287.	1.2	68
45	Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 2013, 108, 250-258.	6.4	64
46	Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecologic Oncology, 2016, 141, 195-198.	1.4	60
47	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Reports, 2021, 36, 109412.	6.4	60
48	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis Journal of Clinical Oncology, 2015, 33, 5508-5508.	1.6	60
49	In Vivo Retargeting of Adenovirus Type 5 to αvβ6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery. Journal of Virology, 2009, 83, 6416-6428.	3.4	59
50	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Current Biology, 2016, 26, 755-765.	3.9	57
51	Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer. Cancer Research, 2011, 71, 3317-3327.	0.9	56
52	The peritoneal tumour microenvironment of highâ€grade serous ovarian cancer. Journal of Pathology, 2012, 227, 136-145.	4.5	54
53	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
54	Management of brain metastases in patients with high-risk gestational trophoblastic tumors. Journal of reproductive medicine, The, 2002, 47, 465-71.	0.2	54

#	Article	IF	CITATIONS
55	Activity of the Adenoviral E1A Deletion Mutant dl922-947 in Ovarian Cancer: Comparison with E1A Wild-type Viruses, Bioluminescence Monitoring, and Intraperitoneal Delivery in Icodextrin. Cancer Research, 2006, 66, 989-998.	0.9	53
56	Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells. Molecular Therapy, 2013, 21, 2074-2086.	8.2	52
57	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
58	Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Annals of Oncology, 2017, 28, 702-710.	1.2	46
59	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
60	Preexisting <i>TP53</i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	7.1	44
61	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
62	Nuclear Survivin Abrogates Multiple Cell Cycle Checkpoints and Enhances Viral Oncolysis. Cancer Research, 2008, 68, 7923-7931.	0.9	41
63	Targeting DNA repair: the genome as a potential biomarker. Journal of Pathology, 2018, 244, 586-597.	4.5	41
64	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1589-1594.	2.5	40
65	Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene, 2003, 22, 3539-3547.	5.9	38
66	Repeatability of Quantitative FDC-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume. Clinical Cancer Research, 2014, 20, 2751-2760.	7.0	38
67	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <scp>PARP</scp> inhibitors. EMBO Molecular Medicine, 2020, 12, e11217.	6.9	37
68	Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. Cell Death and Differentiation, 2001, 8, 256-264.	11.2	36
69	Clear Cell Carcinoma of Ovary and Uterus. Current Oncology Reports, 2013, 15, 566-572.	4.0	36
70	Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1377-1385.	6.4	35
71	Oncolytic virus-induced cell death and immunity: a match made in heaven?. Journal of Leukocyte Biology, 2017, 102, 631-643.	3.3	35
72	Oncologist-led BRCA â€~mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports, 2020, 10, 3390.	3.3	34

#	Article	IF	CITATIONS
73	Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 277-288.	10.7	34
74	Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology, 2017, 145, 2.	1.4	33
75	Proinflammatory Characteristics of SMAC/DIABLO-Induced Cell Death in Antitumor Therapy. Cancer Research, 2012, 72, 1342-1352.	0.9	32
76	Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. Clinical Cancer Research, 2002, 8, 1142-7.	7.0	31
77	Failure of Translation of Human Adenovirus mRNA in Murine Cancer Cells Can be Partially Overcome by L4-100K Expression In Vitro and In Vivo. Molecular Therapy, 2012, 20, 1676-1688.	8.2	30
78	Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. International Journal of Gynecological Cancer, 2021, 31, 161-168.	2.5	30
79	Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer. Oncotarget, 2012, 3, 78-83.	1.8	30
80	NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Molecular Therapy - Oncolytics, 2020, 16, 289-301.	4.4	29
81	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
82	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology, 2015, 9, 791-805.	4.6	27
83	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. Clinical Cancer Research, 2017, 23, 7633-7640.	7.0	27
84	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2021, 27, 3201-3214.	7.0	27
85	The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia. Inflammation, 2021, 44, 1223-1228.	3.8	27
86	Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging. Cancer Research, 2006, 66, 9178-9185.	0.9	25
87	Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. Journal of Clinical Investigation, 2011, 121, 1283-1297.	8.2	25
88	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC) Journal of Clinical Oncology, 2016, 34, 5540-5540.	1.6	25
89	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
90	Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. International Journal of Cancer, 2003, 104, 104-112.	5.1	23

#	Article	IF	CITATIONS
91	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
92	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 969-977.	10.7	23
93	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
94	Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. , 2021, 9, e003645.		23
95	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 2018, 9, 4722-4736.	1.8	22
96	Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB Journal, 2013, 27, 4244-4253.	0.5	21
97	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treatment Reviews, 2021, 100, 102294.	7.7	21
98	A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOC: an International Journal of Obstetrics and Gynaecology, 2008, 115, 808-810.	2.3	20
99	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2017, 28, 459-468.	1.8	20
100	Organoid models in gynaecological oncology research. Cancer Treatment Reviews, 2020, 90, 102103.	7.7	20
101	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	3.1	20
102	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 490-497.	1.4	20
103	Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 522-534.	4.1	20
104	Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. Gene Therapy, 2015, 22, 476-484.	4.5	19
105	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i> -mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer, 2019, 29, 1396-1404.	2.5	19
106	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. Clinical Cancer Research, 2022, 28, 2911-2922.	7.0	19
107	Inhibition of the Inflammatory Cytokine TNF-α Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 Expression. Molecular Therapy, 2011, 19, 490-499.	8.2	18
108	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18

#	Article	IF	CITATIONS
109	p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Molecular Cancer, 2010, 9, 175.	19.2	16
110	RIPK3 promotes adenovirus type 5 activity. Cell Death and Disease, 2017, 8, 3206.	6.3	16
111	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
112	RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. Molecular Cancer Research, 2016, 14, 44-55.	3.4	15
113	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
114	Visualization of cardiac emboli from mitral valve papillary fibroelastoma. Stroke, 1996, 27, 1133-4.	2.0	14
115	The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials, 2011, 32, 8538-8547.	11.4	13
116	Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 2017, 116, 1294-1301.	6.4	13
117	BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1. Gynecologic Oncology, 2017, 145, 5.	1.4	13
118	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
119	2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. European Journal of Cancer, 2015, 51, S531-S532.	2.8	12
120	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
121	Prophylactic <i>In Vivo</i> Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models. Cancer Research, 2020, 80, 549-560.	0.9	12
122	Defining the surgical management of suspected earlyâ€stage ovarian cancer by estimating patient numbers through alternative management strategies. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 1225-1241.	2.3	11
123	Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. Cancer Research, 2015, 75, 2811-2821.	0.9	11
124	7220 Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA). Annals of Oncology, 2021, 32, S725-S726.	1.2	11
125	Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial Journal of Clinical Oncology, 2016, 34, 5549-5549.	1.6	11
126	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2022, 23, 919-930.	10.7	11

#	Article	IF	CITATIONS
127	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
128	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092198.	3.2	8
129	Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. Oncogene, 2021, 40, 3665-3679.	5.9	8
130	Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial Journal of Clinical Oncology, 2021, 39, 5530-5530.	1.6	8
131	Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1037-1044.	2.5	8
132	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response Journal of Clinical Oncology, 2014, 32, TPS5619-TPS5619.	1.6	8
133	Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature. Cancers, 2022, 14, 2708.	3.7	8
134	Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology, 2009, 5, 339-357.	2.4	7
135	Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial. Gynecologic Oncology, 2015, 138, 4.	1.4	7
136	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. International Journal of Gynecological Cancer, 2020, 30, 819-824.	2.5	7
137	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecologic Oncology, 2021, 161, 668-675.	1.4	7
138	Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. Viruses, 2021, 13, 1450.	3.3	7
139	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	4.1	6
140	Generation of Orthotopic Pancreatic Tumors and <i>Ex vivo</i> Characterization of Tumor-Infiltrating T Cell Cytotoxicity. Journal of Visualized Experiments, 2019, , .	0.3	5
141	OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014) Journal of Clinical Oncology, 2017, 35, TPS5609-TPS5609.	1.6	4
142	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
143	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
144	ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer Journal of Clinical Oncology, 2014, 32, TPS5611-TPS5611.	1.6	3

#	Article	IF	CITATIONS
145	NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium Journal of Clinical Oncology, 2016, 34, TPS5603-TPS5603.	1.6	3
146	Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo. International Journal of Molecular Medicine, 2006, 17, 841-7.	4.0	3
147	IL-6 and Ovarian Cancer—Response. Clinical Cancer Research, 2011, 17, 7838-7838.	7.0	2
148	Preliminary Results of Ariel2, a Phase 2 Open-Label Study to Identify Ovarian Cancer Patients Likely to Respond to Rucaparib. Annals of Oncology, 2014, 25, iv308.	1.2	2
149	Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). European Journal of Cancer, 2017, 72, S95.	2.8	2
150	Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?. Clinical Cancer Research, 2018, 24, 5493-5495.	7.0	2
151	8050 ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology, 2020, 31, S610.	1.2	2
152	FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. JCO Clinical Cancer Informatics, 2021, 5, 176-186.	2.1	2
153	A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer Journal of Clinical Oncology, 2015, 33, TPS5611-TPS5611.	1.6	2
154	A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I Journal of Clinical Oncology, 2016, 34, 5543-5543.	1.6	2
155	Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3 Journal of Clinical Oncology, 2018, 36, 5545-5545.	1.6	2
156	Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data. SSRN Electronic Journal, 0, , .	0.4	2
157	Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers. ESMO Open, 2022, 7, 100401.	4.5	2
158	ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology, 2016, 27, vi297.	1.2	1
159	Progression-free survival in the ICON8 trial – Authors' reply. Lancet, The, 2020, 396, 757.	13.7	1
160	TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer Journal of Clinical Oncology, 2016, 34, TPS5604-TPS5604.	1.6	1
161	A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours Journal of Clinical Oncology, 2017, 35, 2594-2594.	1.6	1
162	Author response to: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 1586-1587.	2.3	0

#	Article	IF	CITATIONS
163	Author response to: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOC: an International Journal of Obstetrics and Gynaecology, 2008, 115, 1714-1714.	2.3	0
164	Oncolytic viral gene therapy in ovarian cancer. , 0, , 139-152.		0
165	Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and therapeutics. , 0, , 245-248.		0
166	Role of innate immune responses in the effectiveness of oncolytic adenovirus as an anticancer agent. Lancet, The, 2017, 389, S61.	13.7	0
167	Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy Journal of Clinical Oncology, 2015, 33, 5539-5539.	1.6	0
168	Routine germline BRCA testing in serous ovarian cancer: The West of Scotland experience Journal of Clinical Oncology, 2015, 33, e16532-e16532.	1.6	0
169	Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib , 2016, , .		0
170	44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. Annals of Oncology, 2022, 33, S400-S401.	1.2	0
171	ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer Journal of Clinical Oncology, 2022, 40, TPS5617-TPS5617.	1.6	0
172	Response to the letter entitled "Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers― ESMO Open, 2022, 7, 100534.	4.5	0